Citadel Advisors’s Universe Pharmaceuticals Inc UPC Stock Holding History

Citadel Advisors’s Portfolio UPC Stock Details UPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11	Closed	-$62K	–	14621
2021 Q4	$62K	Buy	+11	New	+$84.5K	﹤0.01%	13121

Other funds holding UPC

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's UPC Position: Q1 2022 in Review

Citadel Advisors sold out of Universe Pharmaceuticals Inc (UPC) in Q1 2022, closing a stake of 11 shares — an estimated $62K sold.

Citadel Advisors first reported a position in UPC in Q4 2021 and held it in 1 quarter. The position peaked at $62K in Q4 2021. 3 funds tracked by Wall St. Rank hold UPC as of Q1 2022.

Citadel Advisors reported no remaining Universe Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
Citadel Advisors sold 11 Universe Pharmaceuticals Inc shares in Q1 2022, an estimated $62K.
Citadel Advisors first reported a position in Universe Pharmaceuticals Inc in Q4 2021 and held it in 1 quarter.
Citadel Advisors's Universe Pharmaceuticals Inc position peaked at $62K in Q4 2021.
3 funds tracked by Wall St. Rank held Universe Pharmaceuticals Inc as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.